Lexicon Pharmaceuticals (LXRX)
(Delayed Data from NSDQ)
$1.12 USD
+0.05 (4.67%)
Updated Aug 4, 2025 04:00 PM ET
Pre-Market: $1.15 +0.03 (2.68%) 9:24 AM ET
3-Hold of 5 3
F Value F Growth F Momentum F VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
LXRX 1.12 +0.05(4.67%)
Will LXRX be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for LXRX based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for LXRX
Alnylam Wins EC Nod for Label Expansion of Amvuttra for ATTR-CM
KURA Stock Rises More Than 15% This Past Week: Here's Why
LXRX: What are Zacks experts saying now?
Zacks Private Portfolio Services
TPST Stock Up on EMA's Orphan Drug Tag for Liver Cancer Therapy
Zoetis Stock Rises 13% in a Month: Time to Add to Your Portfolio?
Lyra Stock Soars 356% in a Week on Strong Rhinosinusitis Study Success
Other News for LXRX
Lexicon (LXRX) Regains Compliance with Nasdaq's Minimum Bid Rule
Lexicon Pharmaceuticals Regains Compliance with Nasdaq Minimum Bid Price Requirement | LXRX ...
Lexicon regains compliance with Nasdaq minimum bid price requirement
Lexicon Pharmaceuticals to Report Second Quarter 2025 Financial Results on August 6, 2025 | ...
Largest borrow rate increases among liquid names